2 completed, 1 recruiting. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Recruiting 1 |
| Phase 2 | 2 | Completed 2 |
Follow Esophagectomy: new trials by email Literature Review of Esophagectomy trials Research Report on Esophagectomy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02) Tislelizumab, Carboplatin, Nab-paclitaxel - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 1 | Recruiting | Shanghai Zhongshan Hospital | 60 | 2025-07-15 | 2026-01-05 |
| Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy for Locally Advanced Esophageal Carcinoma IMRT simultaneous integrated boost, Paclitaxel, Nedaplatin - Esophageal Neoplasms | Phase 1 / Phase 2 | Completed | Chinese Academy of Medical Sciences | 80 | 2015-01-01 | 2017-01-18 |
| Trimodality Management of T1b Esophageal Cancers Docetaxel, 5-FU, Radiotherapy - Esophageal Cancer | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 4 | 2010-10-01 | 2021-04-13 |
Esophageal Neoplasms (2) · Adenocarcinoma (1) · Carcinoma, Squamous Cell (1) · Esophageal Squamous Cell Carcinoma (1)
Chinese Academy of Medical Sciences (1) · M.D. Anderson Cancer Center (1) · Shanghai Zhongshan Hospital (1)
China (2) · United States (1)
Steven H. Lin, MD, PHD (1) · Zefen Xiao, MD (1)
PMID 10235156, PMID 11870157, PMID 12049861, PMID 22565611, PMID 24609941, PMID 26254683, PMID 26808342, PMID 29409469, PMID 29441562, PMID 29861116, PMID 30876442, PMID 31319389, PMID 32143580, PMID 33065643, PMID 34137505, PMID 34454674, PMID 35671803, PMID 36158679, PMID 36322089, PMID 37433041